Focus: Imagin Medical is a public biotechnology company headquartered in Vancouver, BC, specializing in surgical imaging for oncology applications. The company operates a portfolio of radiopharmaceuticals and contrast agents with a primary late-stage asset in neuroendocrine tumor imaging.
Profile data last refreshed 11h ago · AI intelligence enriched 2w ago
Recent layoff filing — 199 affected
Source: state DOL filings via Big Local News
No open roles listed right now. Follow Imagin Medical to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Legacy ANDA product in post-loss-of-exclusivity phase; represents commodity diagnostic imaging market with eroding margins.
Help build intelligence for Imagin Medical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Imagin Medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Post-LOE ANDA radiopharmaceutical; core PET imaging agent competing in mature, generic-saturated market.
NDA-approved somatostatin receptor PET imaging agent; peak-stage asset targeting sstr2-positive neuroendocrine cancers with ~2.5-year market exclusivity remaining.
Duplicate ANDA listing for Fludeoxyglucose F-18; reinforces commodity diagnostic imaging footprint.
Post-LOE ANDA bone imaging radiopharmaceutical; mature commodity PET diagnostic agent.
Duplicate post-LOE ANDA entry; reinforces saturated bone imaging market position.
Post-LOE ANDA iodinated contrast agent; generic iodixanol competitor in commoditized radiology market.
High-concentration post-LOE ANDA contrast formulation; competes in highly generic diagnostic imaging segment.
NDA-listed bone imaging radiopharmaceutical approaching loss of exclusivity; near-term patent cliff risk.
Duplicate post-LOE ANDA bone imaging agent; further reinforces commodity market saturation.
11 discontinued, 5 duplicate formulations not shown
No open positions listed yet.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moSource: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Imminent facility closure and zero active hiring create elevated execution risk; stability concerns warrant careful evaluation of role security and severance protection.